

Global Familial Amyloid Polyneuropathy Therapeutic Market Research Report 2024, Forecast to 2032

<https://marketpublishers.com/r/G7C099BAF22FEN.html>

Date: October 2024

Pages: 141

Price: US\$ 3,400.00 (Single User License)

ID: G7C099BAF22FEN

Abstracts

Report Overview

Familial Amyloid Polyneuropathy (FAP) is a progressive, disabling and life-threatening polyneuropathy affecting the peripheral and autonomic nervous system. FAP is an autosomal transmission disorder which is usually due to a point mutation of the transthyretin (TTR) gene. The treatment of familial amyloid polyneuropathies (FAP) is complex and requires a neurological and cardiological multidisciplinary coverage. It includes specific treatments to control the progression of the systemic amyloidogenesis, the symptomatic treatment of the peripheral and autonomic neuropathy (digestive, urinary, sexual, postural hypotension) and the treatment of organs severely involved by amyloidosis (heart, eyes, kidneys).

The global Familial Amyloid Polyneuropathy Therapeutic market size was estimated at USD 1387 million in 2023 and is projected to reach USD 2323.49 million by 2032, exhibiting a CAGR of 5.90% during the forecast period.

North America Familial Amyloid Polyneuropathy Therapeutic market size was estimated at USD 398.89 million in 2023, at a CAGR of 5.06% during the forecast period of 2024 through 2032.

This report provides a deep insight into the global Familial Amyloid Polyneuropathy Therapeutic market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Familial Amyloid Polyneuropathy Therapeutic Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Familial Amyloid Polyneuropathy Therapeutic market in any manner.

Global Familial Amyloid Polyneuropathy Therapeutic Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Pfizer Inc.

Alnylam Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc.

Corino Therapeutics Inc.

Proclara Biosciences

Arcturus Therapeutics Inc

Prothena Corporation

Eidos Therapeutics

FoldRx Pharmaceuticals

Akcea Therapeutics

GlaxoSmithKline (GSK)

Greenovation Biotech GmbH

Market Segmentation (by Type)

Inotersen

Tafamidis

Patisiran

Others

Market Segmentation (by Application)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Familial Amyloid Polyneuropathy Therapeutic Market

Overview of the regional outlook of the Familial Amyloid Polyneuropathy Therapeutic Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Familial Amyloid Polyneuropathy Therapeutic Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Familial Amyloid Polyneuropathy Therapeutic, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.

Chapter 13 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

- 1.1 Market Definition and Statistical Scope of Familial Amyloid Polyneuropathy Therapeutic
- 1.2 Key Market Segments
 - 1.2.1 Familial Amyloid Polyneuropathy Therapeutic Segment by Type
 - 1.2.2 Familial Amyloid Polyneuropathy Therapeutic Segment by Application
- 1.3 Methodology & Sources of Information
 - 1.3.1 Research Methodology
 - 1.3.2 Research Process
 - 1.3.3 Market Breakdown and Data Triangulation
 - 1.3.4 Base Year
 - 1.3.5 Report Assumptions & Caveats

2 FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTIC MARKET OVERVIEW

- 2.1 Global Market Overview
 - 2.1.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Size (M USD) Estimates and Forecasts (2019-2032)
 - 2.1.2 Global Familial Amyloid Polyneuropathy Therapeutic Sales Estimates and Forecasts (2019-2032)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

3 FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTIC MARKET COMPETITIVE LANDSCAPE

- 3.1 Global Familial Amyloid Polyneuropathy Therapeutic Sales by Manufacturers (2019-2024)
- 3.2 Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Manufacturers (2019-2024)
- 3.3 Familial Amyloid Polyneuropathy Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4 Global Familial Amyloid Polyneuropathy Therapeutic Average Price by Manufacturers (2019-2024)
- 3.5 Manufacturers Familial Amyloid Polyneuropathy Therapeutic Sales Sites, Area Served, Product Type

3.6 Familial Amyloid Polyneuropathy Therapeutic Market Competitive Situation and Trends

3.6.1 Familial Amyloid Polyneuropathy Therapeutic Market Concentration Rate

3.6.2 Global 5 and 10 Largest Familial Amyloid Polyneuropathy Therapeutic Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTIC INDUSTRY CHAIN ANALYSIS

4.1 Familial Amyloid Polyneuropathy Therapeutic Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTIC MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

6 FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTIC MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Familial Amyloid Polyneuropathy Therapeutic Sales Market Share by Type (2019-2024)

6.3 Global Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Type (2019-2024)

6.4 Global Familial Amyloid Polyneuropathy Therapeutic Price by Type (2019-2024)

7 FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTIC MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Sales by Application (2019-2024)
- 7.3 Global Familial Amyloid Polyneuropathy Therapeutic Market Size (M USD) by Application (2019-2024)
- 7.4 Global Familial Amyloid Polyneuropathy Therapeutic Sales Growth Rate by Application (2019-2024)

8 FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTIC MARKET CONSUMPTION BY REGION

- 8.1 Global Familial Amyloid Polyneuropathy Therapeutic Sales by Region
 - 8.1.1 Global Familial Amyloid Polyneuropathy Therapeutic Sales by Region
 - 8.1.2 Global Familial Amyloid Polyneuropathy Therapeutic Sales Market Share by Region
- 8.2 North America
 - 8.2.1 North America Familial Amyloid Polyneuropathy Therapeutic Sales by Country
 - 8.2.2 U.S.
 - 8.2.3 Canada
 - 8.2.4 Mexico
- 8.3 Europe
 - 8.3.1 Europe Familial Amyloid Polyneuropathy Therapeutic Sales by Country
 - 8.3.2 Germany
 - 8.3.3 France
 - 8.3.4 U.K.
 - 8.3.5 Italy
 - 8.3.6 Russia
- 8.4 Asia Pacific
 - 8.4.1 Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Sales by Region
 - 8.4.2 China
 - 8.4.3 Japan
 - 8.4.4 South Korea
 - 8.4.5 India
 - 8.4.6 Southeast Asia
- 8.5 South America
 - 8.5.1 South America Familial Amyloid Polyneuropathy Therapeutic Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTIC MARKET PRODUCTION BY REGION

9.1 Global Production of Familial Amyloid Polyneuropathy Therapeutic by Region (2019-2024)

9.2 Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Region (2019-2024)

9.3 Global Familial Amyloid Polyneuropathy Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)

9.4 North America Familial Amyloid Polyneuropathy Therapeutic Production

9.4.1 North America Familial Amyloid Polyneuropathy Therapeutic Production Growth Rate (2019-2024)

9.4.2 North America Familial Amyloid Polyneuropathy Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)

9.5 Europe Familial Amyloid Polyneuropathy Therapeutic Production

9.5.1 Europe Familial Amyloid Polyneuropathy Therapeutic Production Growth Rate (2019-2024)

9.5.2 Europe Familial Amyloid Polyneuropathy Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)

9.6 Japan Familial Amyloid Polyneuropathy Therapeutic Production (2019-2024)

9.6.1 Japan Familial Amyloid Polyneuropathy Therapeutic Production Growth Rate (2019-2024)

9.6.2 Japan Familial Amyloid Polyneuropathy Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)

9.7 China Familial Amyloid Polyneuropathy Therapeutic Production (2019-2024)

9.7.1 China Familial Amyloid Polyneuropathy Therapeutic Production Growth Rate (2019-2024)

9.7.2 China Familial Amyloid Polyneuropathy Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)

10 KEY COMPANIES PROFILE

10.1 Pfizer Inc.

10.1.1 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Basic Information

10.1.2 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Product Overview

10.1.3 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Product Market Performance

10.1.4 Pfizer Inc. Business Overview

10.1.5 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic SWOT Analysis

10.1.6 Pfizer Inc. Recent Developments

10.2 Alnylam Pharmaceuticals Inc.

10.2.1 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Basic Information

10.2.2 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product Overview

10.2.3 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product Market Performance

10.2.4 Alnylam Pharmaceuticals Inc. Business Overview

10.2.5 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic SWOT Analysis

10.2.6 Alnylam Pharmaceuticals Inc. Recent Developments

10.3 Ionis Pharmaceuticals Inc.

10.3.1 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Basic Information

10.3.2 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product Overview

10.3.3 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product Market Performance

10.3.4 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic SWOT Analysis

10.3.5 Ionis Pharmaceuticals Inc. Business Overview

10.3.6 Ionis Pharmaceuticals Inc. Recent Developments

10.4 Corino Therapeutics Inc.

10.4.1 Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Basic Information

10.4.2 Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Product

Overview

10.4.3 Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Product

Market Performance

10.4.4 Corino Therapeutics Inc. Business Overview

10.4.5 Corino Therapeutics Inc. Recent Developments

10.5 Proclara Biosciences

10.5.1 Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Basic Information

10.5.2 Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Product Overview

10.5.3 Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Product Market Performance

10.5.4 Proclara Biosciences Business Overview

10.5.5 Proclara Biosciences Recent Developments

10.6 Arcturus Therapeutics Inc

10.6.1 Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Basic Information

10.6.2 Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Product Overview

10.6.3 Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Product Market Performance

10.6.4 Arcturus Therapeutics Inc Business Overview

10.6.5 Arcturus Therapeutics Inc Recent Developments

10.7 Prothena Corporation

10.7.1 Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Basic Information

10.7.2 Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Product Overview

10.7.3 Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Product Market Performance

10.7.4 Prothena Corporation Business Overview

10.7.5 Prothena Corporation Recent Developments

10.8 Eidos Therapeutics

10.8.1 Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Basic Information

10.8.2 Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product Overview

10.8.3 Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product Market Performance

- 10.8.4 Eidos Therapeutics Business Overview
- 10.8.5 Eidos Therapeutics Recent Developments
- 10.9 FoldRx Pharmaceuticals
 - 10.9.1 FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Basic Information
 - 10.9.2 FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Product Overview
 - 10.9.3 FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Product Market Performance
 - 10.9.4 FoldRx Pharmaceuticals Business Overview
 - 10.9.5 FoldRx Pharmaceuticals Recent Developments
- 10.10 Akcea Therapeutics
 - 10.10.1 Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Basic Information
 - 10.10.2 Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product Overview
 - 10.10.3 Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product Market Performance
 - 10.10.4 Akcea Therapeutics Business Overview
 - 10.10.5 Akcea Therapeutics Recent Developments
- 10.11 GlaxoSmithKline (GSK)
 - 10.11.1 GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Basic Information
 - 10.11.2 GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Product Overview
 - 10.11.3 GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Product Market Performance
 - 10.11.4 GlaxoSmithKline (GSK) Business Overview
 - 10.11.5 GlaxoSmithKline (GSK) Recent Developments
- 10.12 Greenovation Biotech GmbH
 - 10.12.1 Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Basic Information
 - 10.12.2 Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Product Overview
 - 10.12.3 Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Product Market Performance
 - 10.12.4 Greenovation Biotech GmbH Business Overview
 - 10.12.5 Greenovation Biotech GmbH Recent Developments

11 FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTIC MARKET FORECAST BY REGION

11.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast

11.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Forecast by Region

11.2.1 North America Market Size Forecast by Country

11.2.2 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Country

11.2.3 Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Region

11.2.4 South America Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Country

11.2.5 Middle East and Africa Forecasted Consumption of Familial Amyloid Polyneuropathy Therapeutic by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)

12.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Forecast by Type (2025-2032)

12.1.1 Global Forecasted Sales of Familial Amyloid Polyneuropathy Therapeutic by Type (2025-2032)

12.1.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Type (2025-2032)

12.1.3 Global Forecasted Price of Familial Amyloid Polyneuropathy Therapeutic by Type (2025-2032)

12.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Forecast by Application (2025-2032)

12.2.1 Global Familial Amyloid Polyneuropathy Therapeutic Sales (K MT) Forecast by Application

12.2.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Size (M USD) Forecast by Application (2025-2032)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Familial Amyloid Polyneuropathy Therapeutic Market Size Comparison by Region (M USD)

Table 5. Global Familial Amyloid Polyneuropathy Therapeutic Sales (K MT) by Manufacturers (2019-2024)

Table 6. Global Familial Amyloid Polyneuropathy Therapeutic Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Familial Amyloid Polyneuropathy Therapeutic Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy Therapeutic as of 2022)

Table 10. Global Market Familial Amyloid Polyneuropathy Therapeutic Average Price (USD/MT) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Familial Amyloid Polyneuropathy Therapeutic Sales Sites and Area Served

Table 12. Manufacturers Familial Amyloid Polyneuropathy Therapeutic Product Type

Table 13. Global Familial Amyloid Polyneuropathy Therapeutic Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Familial Amyloid Polyneuropathy Therapeutic

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Familial Amyloid Polyneuropathy Therapeutic Market Challenges

Table 22. Global Familial Amyloid Polyneuropathy Therapeutic Sales by Type (K MT)

Table 23. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (M USD)

Table 24. Global Familial Amyloid Polyneuropathy Therapeutic Sales (K MT) by Type (2019-2024)

Table 25. Global Familial Amyloid Polyneuropathy Therapeutic Sales Market Share by Type (2019-2024)

Table 26. Global Familial Amyloid Polyneuropathy Therapeutic Market Size (M USD) by Type (2019-2024)

Table 27. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Share by Type (2019-2024)

Table 28. Global Familial Amyloid Polyneuropathy Therapeutic Price (USD/MT) by Type (2019-2024)

Table 29. Global Familial Amyloid Polyneuropathy Therapeutic Sales (K MT) by Application

Table 30. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Application

Table 31. Global Familial Amyloid Polyneuropathy Therapeutic Sales by Application (2019-2024) & (K MT)

Table 32. Global Familial Amyloid Polyneuropathy Therapeutic Sales Market Share by Application (2019-2024)

Table 33. Global Familial Amyloid Polyneuropathy Therapeutic Sales by Application (2019-2024) & (M USD)

Table 34. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2019-2024)

Table 35. Global Familial Amyloid Polyneuropathy Therapeutic Sales Growth Rate by Application (2019-2024)

Table 36. Global Familial Amyloid Polyneuropathy Therapeutic Sales by Region (2019-2024) & (K MT)

Table 37. Global Familial Amyloid Polyneuropathy Therapeutic Sales Market Share by Region (2019-2024)

Table 38. North America Familial Amyloid Polyneuropathy Therapeutic Sales by Country (2019-2024) & (K MT)

Table 39. Europe Familial Amyloid Polyneuropathy Therapeutic Sales by Country (2019-2024) & (K MT)

Table 40. Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Sales by Region (2019-2024) & (K MT)

Table 41. South America Familial Amyloid Polyneuropathy Therapeutic Sales by Country (2019-2024) & (K MT)

Table 42. Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Sales by Region (2019-2024) & (K MT)

Table 43. Global Familial Amyloid Polyneuropathy Therapeutic Production (K MT) by Region (2019-2024)

Table 44. Global Familial Amyloid Polyneuropathy Therapeutic Revenue (US\$ Million)

by Region (2019-2024)

Table 45. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Region (2019-2024)

Table 46. Global Familial Amyloid Polyneuropathy Therapeutic Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 47. North America Familial Amyloid Polyneuropathy Therapeutic Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 48. Europe Familial Amyloid Polyneuropathy Therapeutic Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 49. Japan Familial Amyloid Polyneuropathy Therapeutic Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 50. China Familial Amyloid Polyneuropathy Therapeutic Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 51. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Basic Information

Table 52. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Product Overview

Table 53. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 54. Pfizer Inc. Business Overview

Table 55. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic SWOT Analysis

Table 56. Pfizer Inc. Recent Developments

Table 57. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Basic Information

Table 58. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product Overview

Table 59. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 60. Alnylam Pharmaceuticals Inc. Business Overview

Table 61. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic SWOT Analysis

Table 62. Alnylam Pharmaceuticals Inc. Recent Developments

Table 63. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Basic Information

Table 64. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product Overview

Table 65. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 66. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic SWOT Analysis

Table 67. Ionis Pharmaceuticals Inc. Business Overview

Table 68. Ionis Pharmaceuticals Inc. Recent Developments

Table 69. Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Basic Information

Table 70. Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Product Overview

Table 71. Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 72. Corino Therapeutics Inc. Business Overview

Table 73. Corino Therapeutics Inc. Recent Developments

Table 74. Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Basic Information

Table 75. Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Product Overview

Table 76. Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 77. Proclara Biosciences Business Overview

Table 78. Proclara Biosciences Recent Developments

Table 79. Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Basic Information

Table 80. Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Product Overview

Table 81. Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 82. Arcturus Therapeutics Inc Business Overview

Table 83. Arcturus Therapeutics Inc Recent Developments

Table 84. Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Basic Information

Table 85. Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Product Overview

Table 86. Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 87. Prothena Corporation Business Overview

Table 88. Prothena Corporation Recent Developments

Table 89. Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Basic Information

Table 90. Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product Overview

Table 91. Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 92. Eidos Therapeutics Business Overview

Table 93. Eidos Therapeutics Recent Developments

Table 94. FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Basic Information

Table 95. FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Product Overview

Table 96. FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 97. FoldRx Pharmaceuticals Business Overview

Table 98. FoldRx Pharmaceuticals Recent Developments

Table 99. Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Basic Information

Table 100. Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product Overview

Table 101. Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 102. Akcea Therapeutics Business Overview

Table 103. Akcea Therapeutics Recent Developments

Table 104. GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Basic Information

Table 105. GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Product Overview

Table 106. GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 107. GlaxoSmithKline (GSK) Business Overview

Table 108. GlaxoSmithKline (GSK) Recent Developments

Table 109. Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Basic Information

Table 110. Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Product Overview

Table 111. Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 112. Greenovation Biotech GmbH Business Overview

Table 113. Greenovation Biotech GmbH Recent Developments

Table 114. Global Familial Amyloid Polyneuropathy Therapeutic Sales Forecast by Region (2025-2032) & (K MT)

Table 115. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Region (2025-2032) & (M USD)

Table 116. North America Familial Amyloid Polyneuropathy Therapeutic Sales Forecast

by Country (2025-2032) & (K MT)

Table 117. North America Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Country (2025-2032) & (M USD)

Table 118. Europe Familial Amyloid Polyneuropathy Therapeutic Sales Forecast by Country (2025-2032) & (K MT)

Table 119. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Country (2025-2032) & (M USD)

Table 120. Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Sales Forecast by Region (2025-2032) & (K MT)

Table 121. Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Region (2025-2032) & (M USD)

Table 122. South America Familial Amyloid Polyneuropathy Therapeutic Sales Forecast by Country (2025-2032) & (K MT)

Table 123. South America Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Country (2025-2032) & (M USD)

Table 124. Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Consumption Forecast by Country (2025-2032) & (Units)

Table 125. Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Country (2025-2032) & (M USD)

Table 126. Global Familial Amyloid Polyneuropathy Therapeutic Sales Forecast by Type (2025-2032) & (K MT)

Table 127. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Type (2025-2032) & (M USD)

Table 128. Global Familial Amyloid Polyneuropathy Therapeutic Price Forecast by Type (2025-2032) & (USD/MT)

Table 129. Global Familial Amyloid Polyneuropathy Therapeutic Sales (K MT) Forecast by Application (2025-2032)

Table 130. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Application (2025-2032) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Familial Amyloid Polyneuropathy Therapeutic

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Familial Amyloid Polyneuropathy Therapeutic Market Size (M USD), 2019-2032

Figure 5. Global Familial Amyloid Polyneuropathy Therapeutic Market Size (M USD) (2019-2032)

Figure 6. Global Familial Amyloid Polyneuropathy Therapeutic Sales (K MT) & (2019-2032)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (M USD)

Figure 11. Familial Amyloid Polyneuropathy Therapeutic Sales Share by Manufacturers in 2023

Figure 12. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Share by Manufacturers in 2023

Figure 13. Familial Amyloid Polyneuropathy Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023

Figure 14. Global Market Familial Amyloid Polyneuropathy Therapeutic Average Price (USD/MT) of Key Manufacturers in 2023

Figure 15. The Global 5 and 10 Largest Players: Market Share by Familial Amyloid Polyneuropathy Therapeutic Revenue in 2023

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Type

Figure 18. Sales Market Share of Familial Amyloid Polyneuropathy Therapeutic by Type (2019-2024)

Figure 19. Sales Market Share of Familial Amyloid Polyneuropathy Therapeutic by Type in 2023

Figure 20. Market Size Share of Familial Amyloid Polyneuropathy Therapeutic by Type (2019-2024)

Figure 21. Market Size Market Share of Familial Amyloid Polyneuropathy Therapeutic by Type in 2023

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Application

Figure 24. Global Familial Amyloid Polyneuropathy Therapeutic Sales Market Share by Application (2019-2024)

Figure 25. Global Familial Amyloid Polyneuropathy Therapeutic Sales Market Share by Application in 2023

Figure 26. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2019-2024)

Figure 27. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Application in 2023

Figure 28. Global Familial Amyloid Polyneuropathy Therapeutic Sales Growth Rate by Application (2019-2024)

Figure 29. Global Familial Amyloid Polyneuropathy Therapeutic Sales Market Share by Region (2019-2024)

Figure 30. North America Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 31. North America Familial Amyloid Polyneuropathy Therapeutic Sales Market Share by Country in 2023

Figure 32. U.S. Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 33. Canada Familial Amyloid Polyneuropathy Therapeutic Sales (K MT) and Growth Rate (2019-2024)

Figure 34. Mexico Familial Amyloid Polyneuropathy Therapeutic Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 36. Europe Familial Amyloid Polyneuropathy Therapeutic Sales Market Share by Country in 2023

Figure 37. Germany Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 38. France Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 39. U.K. Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 40. Italy Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 41. Russia Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 42. Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Sales and Growth

Rate (K MT)

Figure 43. Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Sales Market Share by Region in 2023

Figure 44. China Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 45. Japan Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 46. South Korea Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 47. India Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 48. Southeast Asia Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 49. South America Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (K MT)

Figure 50. South America Familial Amyloid Polyneuropathy Therapeutic Sales Market Share by Country in 2023

Figure 51. Brazil Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 52. Argentina Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 53. Columbia Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 54. Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (K MT)

Figure 55. Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 57. UAE Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 58. Egypt Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 59. Nigeria Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 60. South Africa Familial Amyloid Polyneuropathy Therapeutic Sales and Growth Rate (2019-2024) & (K MT)

Figure 61. Global Familial Amyloid Polyneuropathy Therapeutic Production Market Share by Region (2019-2024)

Figure 62. North America Familial Amyloid Polyneuropathy Therapeutic Production (K MT) Growth Rate (2019-2024)

Figure 63. Europe Familial Amyloid Polyneuropathy Therapeutic Production (K MT) Growth Rate (2019-2024)

Figure 64. Japan Familial Amyloid Polyneuropathy Therapeutic Production (K MT) Growth Rate (2019-2024)

Figure 65. China Familial Amyloid Polyneuropathy Therapeutic Production (K MT) Growth Rate (2019-2024)

Figure 66. Global Familial Amyloid Polyneuropathy Therapeutic Sales Forecast by Volume (2019-2032) & (K MT)

Figure 67. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Forecast by Value (2019-2032) & (M USD)

Figure 68. Global Familial Amyloid Polyneuropathy Therapeutic Sales Market Share Forecast by Type (2025-2032)

Figure 69. Global Familial Amyloid Polyneuropathy Therapeutic Market Share Forecast by Type (2025-2032)

Figure 70. Global Familial Amyloid Polyneuropathy Therapeutic Sales Forecast by Application (2025-2032)

Figure 71. Global Familial Amyloid Polyneuropathy Therapeutic Market Share Forecast by Application (2025-2032)

I would like to order

Product name: Global Familial Amyloid Polyneuropathy Therapeutic Market Research Report 2024, Forecast to 2032

Product link: <https://marketpublishers.com/r/G7C099BAF22FEN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7C099BAF22FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

